However, whether DOT1L is responsible for pulmonary fibrosis has yet to be fully elucidated, and DOT1L-based approaches may be critical for discovering novel anti-fibrotic therapies, therefore improving clinical outcomes for IPF patients. Here, DOT1L is linked to pulmonary fibrosis.